Partner Headlines - EXEL

  1. Stocks Hitting 52-Week Lows

    Benzinga
  2. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  3. Midday Losers From Tuesday, September 2

    Benzinga
  4. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  5. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  6. Stocks Hitting 52-Week Lows

    Benzinga
  7. Morning Market Losers

    Benzinga
  8. Benzinga's Top Downgrades

    Benzinga
  9. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  10. Stocks To Watch For September 2, 2014

    Benzinga
  11. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  12. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  13. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  14. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  15. Morning Market Movers

    Benzinga
  16. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  19. Benzinga's Top #PreMarket Gainers

    Benzinga
  20. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  21. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  22. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  23. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  24. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  25. Stocks Hitting 52-Week Lows

    Benzinga
  26. Morning Market Losers

    Benzinga
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. Morning Market Movers

    Benzinga
  29. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  30. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  31. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  32. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  33. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  34. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  35. US Stock Futures Up After Upbeat China Data

    Benzinga
  36. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  37. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  38. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  39. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  40. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  41. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  42. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  43. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  44. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  45. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  46. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  47. Health Care Sector Wrap

    FoxBusiness
  48. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  49. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  50. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  51. Exelixis Proposed Offering 20M Shares

    Benzinga
  52. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  53. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  54. Benzinga's Top Pre-Market Gainers

    Benzinga
  55. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  56. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  57. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  58. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  59. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  60. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  61. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  62. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  63. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  64. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  65. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  66. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  67. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  68. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  69. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  70. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  71. Notable Call Options Activity on Exelixis

    Benzinga
  72. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  73. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center